IZUChENIE PERENOSIMOSTI ALENDRONATA 70 MG (FOSAMAKS 70 MG ODIN RAZ V NEDELYu) I PRIChINOTMENY LEChENIYa U BOL'NYKh POSTMENOPAUZAL'NYMOSTEOPOROZOM V USLOVIYaKh REAL'NOY KLINIChESKOYPRAKTIKI

The aim of study was tolerability and causes of discontinuation to alendronate 70 mg OW therapy in nonresearch real world setting. We prospectively analyzed 427 female patients (67+8,2years) newly prescribed with alendronate 70mg OW for postmenopausal osteoporosis and followed up during a year. The background of GI diseases was reported in 64% of patients, while 36% were receiving three or more concomitant medications. 30% of patients discontinued therapy throughout the year. The most frequent reasons for treatment discontinuation were unaffordable price of alendronate (20% of all patients; 68% of all discontinuation cases) and GI complaints (9%;29,6%), despite most cases were not assumed to be related to the drug. There were only 3 cases of intolerance to alendronate (0,7%;2,3%). In persistent patients alendornate was overall well tolerated; in 22% of them minor or mild dyspepsia was reported. The incidence of dyspepsia was not associated with the presence of GI diseases (p=0,953). The study suggests that a large proportion of GI adverse experiences seen on aledronate treatment may not have causal relationship to therapy. The high rate of GI diseases and concomitant drugs in osteoporosis patients are underestimated in clinical practice.